HARP Stock Overview
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases in the United States.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$5.44|
|52 Week High||US$25.24|
|52 Week Low||US$5.37|
|1 Month Change||-21.16%|
|3 Month Change||-21.16%|
|1 Year Change||-77.48%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-59.70%|
Recent News & Updates
We're Keeping An Eye On Harpoon Therapeutics' (NASDAQ:HARP) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
|HARP||US Biotechs||US Market|
Return vs Industry: HARP underperformed the US Biotechs industry which returned -18.4% over the past year.
Return vs Market: HARP underperformed the US Market which returned 10.2% over the past year.
|HARP Average Weekly Movement||11.6%|
|Biotechs Industry Average Movement||10.1%|
|Market Average Movement||6.6%|
|10% most volatile stocks in US Market||15.8%|
|10% least volatile stocks in US Market||2.4%|
Stable Share Price: HARP is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: HARP's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases in the United States. The company's lead tri-specific t-cell activating construct (TriTAC) product candidate is HPN424, which is in Phase I/IIa clinical trials for the treatment of metastatic castration-resistant prostate cancer. It is also developing HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian cancer and other mesothelin-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN328, a product candidate in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors.
Harpoon Therapeutics Fundamentals Summary
|HARP fundamental statistics|
Is HARP overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|HARP income statement (TTM)|
|Cost of Revenue||US$66.53m|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-3.25|
|Net Profit Margin||-397.17%|
How did HARP perform over the long term?See historical performance and comparison
Is Harpoon Therapeutics undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: HARP ($5.44) is trading below our estimate of fair value ($161.73)
Significantly Below Fair Value: HARP is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: HARP is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: HARP is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate HARP's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: HARP is overvalued based on its PB Ratio (2.3x) compared to the US Biotechs industry average (2.1x).
How is Harpoon Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: HARP is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: HARP is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: HARP is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: HARP's revenue (44.3% per year) is forecast to grow faster than the US market (9.2% per year).
High Growth Revenue: HARP's revenue (44.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: HARP is forecast to be unprofitable in 3 years.
How has Harpoon Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: HARP is currently unprofitable.
Growing Profit Margin: HARP is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: HARP is unprofitable, and losses have increased over the past 5 years at a rate of 38.5% per year.
Accelerating Growth: Unable to compare HARP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: HARP is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (11%).
Return on Equity
High ROE: HARP has a negative Return on Equity (-138.4%), as it is currently unprofitable.
How is Harpoon Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: HARP's short term assets ($156.2M) exceed its short term liabilities ($55.4M).
Long Term Liabilities: HARP's short term assets ($156.2M) exceed its long term liabilities ($42.3M).
Debt to Equity History and Analysis
Debt Level: HARP is debt free.
Reducing Debt: HARP had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: HARP has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: HARP has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of 31% each year.
What is Harpoon Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate HARP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate HARP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if HARP's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if HARP's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of HARP's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Julie Eastland (57 yo)
Ms. Julie M. Eastland has been an Independent Non-Employee Director at Graybug Vision, Inc. since September 25, 2020. Ms. Eastland serves as Director at Dynavax Technologies Corporation since July 2020. Ms...
Experienced Management: HARP's management team is considered experienced (3.3 years average tenure).
Experienced Board: HARP's board of directors are considered experienced (3.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Harpoon Therapeutics, Inc.'s employee growth, exchange listings and data sources
- Name: Harpoon Therapeutics, Inc.
- Ticker: HARP
- Exchange: NasdaqGS
- Founded: 2015
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$178.152m
- Shares outstanding: 32.75m
- Website: https://www.harpoontx.com
Number of Employees
- Harpoon Therapeutics, Inc.
- 131 Oyster Point Boulevard
- Suite 300
- South San Francisco
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/01/19 00:11|
|End of Day Share Price||2022/01/18 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.